{"id":82591,"date":"2025-11-17T11:23:00","date_gmt":"2025-11-17T11:23:00","guid":{"rendered":"https:\/\/www.cofb.org\/?p=82591"},"modified":"2025-11-20T14:26:12","modified_gmt":"2025-11-20T14:26:12","slug":"el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/","title":{"rendered":"El paper de la farm\u00e0cia en la cura de la pell en el c\u00e0ncer de mama"},"content":{"rendered":"\n

El passat 24 d\u2019octubre, al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB)<\/strong> es va celebrar la confer\u00e8ncia \u201cCura de la pell en el c\u00e0ncer de mama<\/strong>\u201d, amb la col\u00b7laboraci\u00f3 de La Roche Posay<\/a>. La sessi\u00f3 va comptar amb la participaci\u00f3 de Milana Bergamino<\/strong>, onc\u00f2loga de l\u2019Hospital Cl\u00ednic de Barcelona i integrant del Translational Genomics and Target Therapies in Solid Tumours Lab a Idibaps; Jes\u00fas P\u00e9rez,<\/strong> diplomat en tecnologia cardiopulmonar i corresponsable del Departament d\u2019Oncologia de La Roche Posay; Marta de la Fuente<\/strong>, psic\u00f2loga sanit\u00e0ria, psicoonc\u00f2loga, especialista en ansietat i estr\u00e8s i directora del Centro Sanitario MFL Psicolog\u00eda y Formaci\u00f3n a Coru\u00f1a; i Clara Ros\u00e1s<\/strong>, gerent de la Federaci\u00f3 Catalana d’Entitats Contra el C\u00e0ncer. Marta Alcalde<\/strong>, vocal de Dermofarm\u00e0cia i Productes Sanitaris del COFB, va moderar la formaci\u00f3.<\/p>\n\n\n\n

\"Marta<\/a>
Marta Alcalde, vocal del COFB, va presentar la formaci\u00f3 \u201cCura de la pell en el c\u00e0ncer de mama\u201d.<\/figcaption><\/figure>\n\n\n\n

Els objectius <\/strong>de la confer\u00e8ncia, adre\u00e7ada a farmac\u00e8utics i farmac\u00e8utiques comunit\u00e0ries, van ser actualitzar coneixements en c\u00e0ncer de mama<\/strong>, donar a con\u00e8ixer els tractaments de primera elecci\u00f3 <\/strong>en patologies d\u00e8rmiques freq\u00fcents en pacients oncol\u00f2gics, revisar l\u2019algoritme de recomanacions cosm\u00e8tiques<\/strong> en pacients oncol\u00f2gics, dotar d\u2019eines de comunicaci\u00f3 per atendre el pacient <\/strong>o el seu cuidador i assimilar de manera pr\u00e0ctica i did\u00e0ctica els diferents conceptes apresos<\/strong> que faciliten una indicaci\u00f3 senzilla i efica\u00e7.<\/p>\n\n\n\n

En la presentaci\u00f3 de la formaci\u00f3, Marta Alcalde<\/strong>, vocal de Dermofarm\u00e0cia i Productes Sanitaris del COFB, <\/strong>va explicar que \u201ca la farm\u00e0cia es tenen consultes relacionades amb el c\u00e0ncer de mama<\/strong>. Els efectes secundaris en l\u2019\u00e0mbit cutani <\/strong>s\u00f3n habituals en els tractaments contra aquesta malaltia i durant la jornada s\u2019analitzaran amb quins abordatges es compten avui dia\u201d. A m\u00e9s, Alcalde va recordar que \u201ces tracta d\u2019una patologia molt heterog\u00e8nia<\/strong>, la poden tenir molts pacients i els efectes secundaris ser for\u00e7a diversos\u201d.<\/p>\n\n\n\n

Factors de risc i tipus de c\u00e0ncer de mama<\/h2>\n\n\n\n

En la primera de les presentacions, Milana Bergamino<\/strong> la va arrencar recordant que \u201ctenir una farm\u00e0cia de confian\u00e7a <\/strong>\u00e9s fonamental per aquells pacients que pateixen de la pell pel fet que pateixen c\u00e0ncer de mama\u201d. Aquesta malaltia \u201c\u00e9s la m\u00e9s freq\u00fcent del m\u00f3n i en la dona \u00e9s la que provoca un major empitjorament de la qualitat de vida\u201d. Pel que fa als factors de risc<\/strong>, l’onc\u00f2loga de l’Hospital Cl\u00ednic va destacar que \u201cs\u00f3n m\u00faltiples, dif\u00edcils de distingir i no \u00e9s clar quin pes pot tenir cadascun, i per aix\u00f2 \u00e9s multicausal\u201d.<\/p>\n\n\n\n

\"Milana<\/a>
Milana Bergamino, durant un moment de la seva presentaci\u00f3.<\/figcaption><\/figure>\n\n\n\n

Pel que fa als tipus de c\u00e0ncer de mama<\/strong>, \u201caquests es divideixen en localitzats i avan\u00e7ats<\/strong>, on la cirurgia, radioter\u00e0pia o els tractaments sist\u00e8mics tenen un paper important. A m\u00e9s, necessiten un diagn\u00f2stic multidisciplinari<\/strong> i una classificaci\u00f3 patol\u00f2gica o molecular que permet als experts distingir-los millor\u201d, va descriure l\u2019especialista.<\/p>\n\n\n\n

La toxicitat cut\u00e0nia en pacients oncol\u00f2gics<\/h2>\n\n\n\n

Analitzar si els productes cosm\u00e8tics<\/strong> s\u00f3n segurs per tractar la pell de pacients amb c\u00e0ncer de mama va ser analitzat per Jes\u00fas P\u00e9rez<\/strong>: \u201cMoltes cremes <\/strong>que es venen a les farm\u00e0cies han estat analitzades en pells sanes<\/strong>, per\u00f2 no han sigut testades en pacients oncol\u00f2gics<\/strong>. Depenent del tipus d\u2019hormones o del tractament que rebi el pacient, hi ha una gran quantitat d\u2019elements adversos\u201d.<\/p>\n\n\n\n

\"Jes\u00fas<\/a>
Jes\u00fas P\u00e9rez, en un moment de la seva exposici\u00f3.<\/figcaption><\/figure>\n\n\n\n

A m\u00e9s, el corresponsable del Departament d\u2019Oncologia de La Roche Posay va recalcar que \u201cm\u00e9s del 70% d\u2019aquests pacients<\/strong> han hagut de reduir les dosis de tractament o parar-lo <\/strong>a causa de la toxicitat cut\u00e0nia que patien. Els elements adversos que pateix la pell del pacient s\u00f3n importants en el seu dia a dia, juntament amb qu\u00e8 no reben recomanacions dermatol\u00f2giques<\/strong> per a aquestes situacions\u201d. Per finalitzar, l\u2019especialista va advertir que \u201cs\u2019ha d\u2019anar amb compte amb els productes naturals i ecol\u00f2gics<\/strong> com els remeis d\u2019herbes si s\u2019est\u00e0 duent a terme un tractament contra el c\u00e0ncer, ja que molts s\u00f3n perjudicials per a la pell\u201d.<\/p>\n\n\n\n

Gesti\u00f3 emocional dels pacients amb c\u00e0ncer de mama<\/h2>\n\n\n\n

Marta de la Fuente<\/strong> va explicar en la seva pon\u00e8ncia la import\u00e0ncia de dur una gesti\u00f3 emocional dels pacients amb c\u00e0ncer de mama<\/strong>: \u201cEs coneixen els efectes secundaris dels pacients<\/strong>, per\u00f2 es desconeix la magnitud o incapacitat que pot arribar a tenir. Els tractaments <\/strong>poden arribar a perdurar fins a deu anys<\/strong> i si no es cuida la qualitat de vida, el pacient l\u2019acaba abandonant, ja que no hi ha una bona gesti\u00f3 emocional\u201d.<\/p>\n\n\n\n

\"La<\/a>
La gesti\u00f3 emocional dels pacients amb c\u00e0ncer de mama va ser analitzada per Marta de la Fuente.<\/figcaption><\/figure>\n\n\n\n

La salut emocional de la dona gira entorn de \u201cl\u2019autoexig\u00e8ncia creada <\/strong>per aspectes apresos des de la inf\u00e0ncia<\/strong>. Ens persegueixen determinades creences que durant un proc\u00e9s oncol\u00f2gic acaben afectant el fet de no demanar ajuda, voler agradar al nostre entorn<\/strong> o es passa incl\u00fas per la incomprensi\u00f3 <\/strong>pel que fa a la sexualitat<\/strong>\u201d, va explicar la psic\u00f2loga sanit\u00e0ria, recordant que \u201cs\u2019han de desmuntar aquestes percepcions als pacients que venen a les farm\u00e0cies\u201d.<\/p>\n\n\n\n

El paper dels pacients<\/h2>\n\n\n\n

\u201cEl c\u00e0ncer t\u00e9 una alta incid\u00e8ncia <\/strong>i arriba a generar 24.000 casos nous a l\u2019any entre els homes i 18.000 entre les dones\u201d, va afirmar Clara Ros\u00e1s <\/strong>durant la seva intervenci\u00f3. En aquest context, va indicar que \u201cla irrupci\u00f3 de noves eines terap\u00e8utiques<\/strong> ha provocat que les taxes de superviv\u00e8ncia <\/strong>hagin augmentat <\/strong>de manera considerable. Ara b\u00e9, un cop se supera el c\u00e0ncer, els tractaments poden deixar seq\u00fceles que s\u2019han de gestionar<\/strong>\u201d.<\/p>\n\n\n\n

\"Clara<\/a>
Clara Ros\u00e1s va descriure les funcions que duu a terme la Federaci\u00f3 Catalana d’Entitats Contra el C\u00e0ncer.<\/figcaption><\/figure>\n\n\n\n

En aquest sentit, la gerent de la FECEC va contextualitzar la Federaci\u00f3 Catalana d’Entitats Contra el C\u00e0ncer<\/strong>, recordant que \u201cagrupa 16 entitats<\/strong> de pacients a tot Catalunya i totes elles van n\u00e9ixer despr\u00e9s d\u2019identificar que la part emocional i social<\/strong> dels pacients oncol\u00f2gics quedava desatesa<\/strong>. Des de la societat civil han sorgit iniciatives com aquesta per ajudar al benestar de tots aquest proc\u00e9s\u201d. Per finalitzar, va recordar que la instituci\u00f3 \u201cest\u00e0 present durant tot el proc\u00e9s, comen\u00e7ant pel tractament i acabant amb les cures pal\u00b7liatives\u201d.<\/p>\n\n\n\n

Amb la col\u00b7laboraci\u00f3 de:<\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"

El passat 24 d\u2019octubre, al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) es va celebrar la confer\u00e8ncia \u201cCura de la pell en el c\u00e0ncer de mama\u201d, amb la col\u00b7laboraci\u00f3 de La Roche Posay. La sessi\u00f3 va comptar amb la participaci\u00f3 de Milana Bergamino, onc\u00f2loga de l\u2019Hospital Cl\u00ednic de Barcelona i integrant […]<\/p>\n","protected":false},"author":10,"featured_media":82608,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[23,57],"tags":[753,18,19,169,70,982,710,3658,63],"class_list":["post-82591","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-destacats","category-mon-collegial","tag-cancer-de-mama","tag-cofb","tag-collegi-de-farmaceutics-de-barcelona","tag-cures-palliatives","tag-formacio","tag-pacient-amb-cancer","tag-pell","tag-riscos","tag-tractament"],"yoast_head":"\nEl paper de la farm\u00e0cia en la cura de la pell en el c\u00e0ncer de mama - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"El COFB va organitzar la formaci\u00f3 \u201cCura de la pell en el c\u00e0ncer de mama\u201d, amb la col\u00b7laboraci\u00f3 de La Roche Posay\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cofb.org\/ca\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"El paper de la farm\u00e0cia en la cura de la pell en el c\u00e0ncer de mama - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El COFB va organitzar la formaci\u00f3 \u201cCura de la pell en el c\u00e0ncer de mama\u201d, amb la col\u00b7laboraci\u00f3 de La Roche Posay\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cofb.org\/ca\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-17T11:23:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-20T14:26:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Xavier Magraner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Xavier Magraner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/\"},\"author\":{\"name\":\"Xavier Magraner\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4\"},\"headline\":\"El paper de la farm\u00e0cia en la cura de la pell en el c\u00e0ncer de mama\",\"datePublished\":\"2025-11-17T11:23:00+00:00\",\"dateModified\":\"2025-11-20T14:26:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/\"},\"wordCount\":1144,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-scaled.jpg\",\"keywords\":[\"c\u00e0ncer de mama\",\"COFB\",\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"cures pal\u00b7liatives\",\"Formaci\u00f3\",\"pacient amb c\u00e0ncer\",\"pell\",\"riscos\",\"tractament\"],\"articleSection\":[\"Destacats\",\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/\",\"url\":\"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/\",\"name\":\"El paper de la farm\u00e0cia en la cura de la pell en el c\u00e0ncer de mama - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-scaled.jpg\",\"datePublished\":\"2025-11-17T11:23:00+00:00\",\"dateModified\":\"2025-11-20T14:26:12+00:00\",\"description\":\"El COFB va organitzar la formaci\u00f3 \u201cCura de la pell en el c\u00e0ncer de mama\u201d, amb la col\u00b7laboraci\u00f3 de La Roche Posay\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/#primaryimage\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-scaled.jpg\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-scaled.jpg\",\"width\":2560,\"height\":1440},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"El paper de la farm\u00e0cia en la cura de la pell en el c\u00e0ncer de mama\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4\",\"name\":\"Xavier Magraner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g\",\"caption\":\"Xavier Magraner\"},\"url\":\"https:\/\/www.cofb.org\/ca\/author\/xmagraner\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"El paper de la farm\u00e0cia en la cura de la pell en el c\u00e0ncer de mama - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"El COFB va organitzar la formaci\u00f3 \u201cCura de la pell en el c\u00e0ncer de mama\u201d, amb la col\u00b7laboraci\u00f3 de La Roche Posay","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cofb.org\/ca\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/","og_locale":"ca_ES","og_type":"article","og_title":"El paper de la farm\u00e0cia en la cura de la pell en el c\u00e0ncer de mama - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"El COFB va organitzar la formaci\u00f3 \u201cCura de la pell en el c\u00e0ncer de mama\u201d, amb la col\u00b7laboraci\u00f3 de La Roche Posay","og_url":"https:\/\/www.cofb.org\/ca\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2025-11-17T11:23:00+00:00","article_modified_time":"2025-11-20T14:26:12+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-scaled.jpg","type":"image\/jpeg"}],"author":"Xavier Magraner","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"Xavier Magraner","Temps estimat de lectura":"7 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/#article","isPartOf":{"@id":"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/"},"author":{"name":"Xavier Magraner","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4"},"headline":"El paper de la farm\u00e0cia en la cura de la pell en el c\u00e0ncer de mama","datePublished":"2025-11-17T11:23:00+00:00","dateModified":"2025-11-20T14:26:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/"},"wordCount":1144,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-scaled.jpg","keywords":["c\u00e0ncer de mama","COFB","Col\u00b7legi de Farmac\u00e8utics de Barcelona","cures pal\u00b7liatives","Formaci\u00f3","pacient amb c\u00e0ncer","pell","riscos","tractament"],"articleSection":["Destacats","M\u00f3n col\u00b7legial"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/","url":"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/","name":"El paper de la farm\u00e0cia en la cura de la pell en el c\u00e0ncer de mama - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/#primaryimage"},"image":{"@id":"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-scaled.jpg","datePublished":"2025-11-17T11:23:00+00:00","dateModified":"2025-11-20T14:26:12+00:00","description":"El COFB va organitzar la formaci\u00f3 \u201cCura de la pell en el c\u00e0ncer de mama\u201d, amb la col\u00b7laboraci\u00f3 de La Roche Posay","breadcrumb":{"@id":"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/#primaryimage","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-scaled.jpg","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-scaled.jpg","width":2560,"height":1440},{"@type":"BreadcrumbList","@id":"https:\/\/www.cofb.org\/2025\/11\/17\/el-paper-de-la-farmacia-en-la-cura-de-la-pell-en-el-cancer-de-mama\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"El paper de la farm\u00e0cia en la cura de la pell en el c\u00e0ncer de mama"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4","name":"Xavier Magraner","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g","caption":"Xavier Magraner"},"url":"https:\/\/www.cofb.org\/ca\/author\/xmagraner\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-scaled.jpg",2560,1440,false],"thumbnail":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-150x150.jpg",150,150,true],"medium":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-300x169.jpg",300,169,true],"medium_large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-768x432.jpg",768,432,true],"large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-1024x576.jpg",1024,576,true],"1536x1536":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-1536x864.jpg",1536,864,true],"2048x2048":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-2048x1152.jpg",2048,1152,true],"trp-custom-language-flag":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_MAMA_27102025_00-18x10.jpg",18,10,true]},"uagb_author_info":{"display_name":"Xavier Magraner","author_link":"https:\/\/www.cofb.org\/ca\/author\/xmagraner\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat 24 d\u2019octubre, al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) es va celebrar la confer\u00e8ncia \u201cCura de la pell en el c\u00e0ncer de mama\u201d, amb la col\u00b7laboraci\u00f3 de La Roche Posay. La sessi\u00f3 va comptar amb la participaci\u00f3 de Milana Bergamino, onc\u00f2loga de l\u2019Hospital Cl\u00ednic de Barcelona i integrant […]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/82591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=82591"}],"version-history":[{"count":16,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/82591\/revisions"}],"predecessor-version":[{"id":82920,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/82591\/revisions\/82920"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media\/82608"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=82591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=82591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=82591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}